Loading…
Swiss maker of titanium plates and screws for surgical fixation of small and mid-sized bones.
Swiss maker of titanium plates and screws for surgical fixation of small and mid-sized bones.
Sells implants to hospitals one operation at a time, with its instrument sets placed on loan so surgeons train on its system and keep using it; it sells directly in its main markets and through distributors elsewhere. Based in Basel, Switzerland.
In one line: A small Swiss extremities-trauma implant specialist.
Moat: narrow (switching costs, brand, distribution). Surgeon familiarity with instrument sets and distribution in a niche extremities segment.
Headquarters: Basel, Switzerland · Founded: 1997 · Employees: 1,337
Size Medartis (MED.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $1.83B, the 96th largest of 158 Switzerland companies the cockpit tracks. Shares closed at CHF 109.60 on 6 Nov 2026.
Performance Over six months the shares gained 47.1%, against -4.5% for the median peer and +11.6% for the Switzerland market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 29.9% over the last twelve months (peer median +10.6%); the operating margin is 1.6% (peer median 11.5%).
Valuation It trades at 74.2× forward earnings against a peer median of 26.9× (most expensive of 18).
Capital Return on invested capital runs 6.1 points below its cost of capital (7.0% WACC).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 307M | CHF 269M | CHF 225M | CHF 212M | CHF 183M |
| Revenue growth | — | +20% | +6% | +16% | — |
| Gross profit | CHF 238M | CHF 186M | CHF 162M | CHF 152M | CHF 135M |
| EBITDA | CHF 33.9M | CHF 25.6M | CHF 35.2M | CHF 32.4M | CHF 16.2M |
| Net income | CHF 14.9M | CHF 8.35M | CHF 3.53M | CHF 619,000 | -CHF 5.78M |
| Free cash flow | CHF 1.21M | CHF 12.3M | CHF 21.0M | CHF 5.03M | -CHF 19.4M |
| Capital expenditure | CHF 35.2M | CHF 25.5M | CHF 11.1M | CHF 18.8M | CHF 18.8M |
| Total debt | n/a | CHF 158M | CHF 121M | CHF 42.2M | CHF 52.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Medartis MED.SW | $1.83B | +47% | +30% | 2% | 74.2× | n/a |
| Stryker SYK | $124B | +14% | +8% | 25% | 20.4× | 10.6% |
| Zimmer Biomet ZBH | $20.1B | +29% | +7% | 16% | 12.0× | -1.4% |
| Johnson & Johnson JNJ | $665B | +26% | +8% | 26% | 24.5× | 3.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MED.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +34.3% | -0.5% | highest of 21 |
| 6-month return | +47.1% | -4.5% | 4th highest of 21 |
| Distance from 52-week high | -1.3% | -31.4% | highest of 21 |
| Revenue growth (TTM) | +29.9% | +10.6% | 7th highest of 21 |
| Operating margin | 1.6% | 11.5% | 4th lowest of 21 |
| Forward P/E | 74.2× | 26.9× | most expensive of 18 |
| ROIC minus cost of capital | -6.1 pp | +1.1 pp | 6th lowest of 21 |
| EV / EBITDA | 49.5× | 13.7× | most expensive of 12 |
| Net debt / EBITDA | 5.4× | -1.1× | most indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Medartis MED.SW | Switzerland | $1.83B | +47% | +30% | 2% | 74.2× | n/a | n/a |
| Inner Mongolia Furui Medical Science 300049.SZ | China | $1.85B | -5% | +11% | 25% | 53.2× | 6.6% | +14.6% |
| LeMaitre Vascular LMAT | United States | $1.85B | -25% | +12% | 29% | 26.2× | 2.9% | +14.0% |
| Inspire Medical Systems INSP | United States | $1.85B | +45% | 0% | 2% | 45.4× | 30.9% | +51.2% |
| Wuxi Unicomp Technology 688531.SS | China | $1.80B | -36% | +53% | 12% | 40.7× | n/a | n/a |
| DENTSPLY SIRONA XRAY | United States | $1.89B | -14% | -1% | 5% | 7.3× | 10.2% | +1.9% |
| Draegerwerk AG & Co. KGaA DRW8.DE | Germany | $1.89B | +17% | +5% | 7% | 9.4× | -12.6% | +0.4% |
| Fukuda Denshi 6960.T | Japan | $1.75B | -5% | 0% | 19% | 14.6× | -3.2% | -1.0% |
| SKAN SKAN.SW | Switzerland | $1.92B | +49% | +9% | 11% | 49.8× | 13.8% | +11.7% |
| Embla Medical hf EMBLA.CO | Denmark | $1.75B | +3% | +6% | 14% | 17.9× | -1.8% | +8.3% |
| Angelalign Technology 6699.HK | Hong Kong | $1.74B | -7% | +84% | 9% | 52.1× | 18.1% | +25.8% |
| Poly Medicure POLYMED.NS | India | $1.73B | -4% | +18% | 17% | 40.6× | n/a | n/a |
| Veracyte VCYT | United States | $1.94B | -40% | +17% | 17% | 14.9× | 15.1% | +34.5% |
| Mehow Innovative 301363.SZ | China | $1.95B | -14% | +10% | 21% | 38.8× | 18.9% | +12.9% |
| Kestra Medical Technologies KMTS | United States | $1.72B | +37% | +61% | -134% | n/a | n/a | n/a |
| Cofoe Medical Technology 301087.SZ | China | $1.71B | -5% | +33% | 10% | 26.9× | 12.5% | +7.4% |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.96B | -4% | +7% | 14% | 8.8× | -11.8% | +2.1% |
| Butterfly Network BFLY | United States | $1.70B | +53% | +39% | -36% | n/a | n/a | n/a |
| JEOL 6951.T | Japan | $1.98B | -3% | -18% | 11% | 14.2× | 21.3% | +10.2% |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.69B | +124% | +3% | 49% | 52.0× | 17.9% | +12.7% |
| Establishment Labs ESTA | United States | $2.00B | -7% | +38% | -7% | n/a | n/a | n/a |